TEAD Inhibition for Lung Metastasis Immune Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lung metastasis, particularly in triple negative breast cancer (TNBC), is a significant challenge with high mortality rates due to the aggressive metastatic nature of the disease, and current treatments only benefit a small subset of patients.
Innovation Solution
The use of TEAD inhibitors to target a population of cancer cells expressing AIB1A4, reducing invasive ability and suppressing lung metastases by enhancing T-cell and alveolar macrophage activity, and shifting macrophage polarization from pro-tumor to anti-tumor M1-like macrophages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapy, immunotherapy, and targeted therapies are used to treat metastatic TNBC, then some patients may benefit, but the treatment only benefits a small subset of patients and has high mortality rates
Solution Approach 1:
The patent changes the therapeutic parameter from general chemotherapy/immunotherapy to targeted TEAD inhibition. By specifically targeting the TEAD transcription factor pathway that is upregulated in metastatic TNBC cells, the treatment achieves reliable efficacy in patients with this specific molecular profile, reducing the variability in patient response while maintaining high treatment effectiveness.
2Reliability
If TEAD inhibitors are used to suppress lung metastases, then metastatic outgrowth is reduced, but the mechanism involves complex immune modulation including T-cell infiltration and macrophage polarization
Solution Approach 1:
The patent uses TEAD inhibitors as an intermediary molecule that indirectly modulates the immune microenvironment. Rather than directly activating T-cells or macrophages, the inhibitor targets cancer cell TEAD pathways, which secondarily leads to immune cell infiltration and macrophage polarization changes. This intermediary approach simplifies the therapeutic mechanism while achieving reliable metastasis suppression through coordinated immune responses.
3Reliability
If TEAD inhibition is used to reduce invasive ability of tumor spheres, then metastatic potential is decreased, but this requires specific targeting of AIB1A4-expressing cancer cell populations
Solution Approach 1:
The patent applies local quality by targeting specific molecular characteristics (AIB1A4 expression and TEAD pathway activation) of the invasive cancer cell population. Rather than treating all cancer cells uniformly, the therapy specifically addresses the subset of cells with high metastatic potential, identified by their unique molecular profile. This localized targeting approach reliably reduces invasive ability while avoiding unnecessary treatment of non-invasive cells.
Data Source
AI summary
Method of treating secondary cancer in a lung of a subject in need thereof, comprising administering a pharmaceutical composition comprising an effective amount of an inhibitor of transcriptional enhanced associate domain (TEAD) to the subject. In addition, methods of inhibiting growth of a secondary tumor in a lung of a subject in need thereof, of increasing number of T-cells at a secondary tumor in a lung of a subject in need thereof, of increasing number of alveolar macrophages in a lung of a subject in need thereof, of decreasing number of infiltrating monocytes/macrophages in a lung of a subject in need thereof, methods of reducing lung metastases in a subject in need thereof, method of inducing polarization of one or more M2 macrophages to M1 macrophages in the lung of a subject with lung cancer, and methods of activating IL12 signaling in lung of a subject with lung cancer.